Actively Recruiting
Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
Led by Nebraska Methodist Health System · Updated on 2024-04-12
600
Participants Needed
1
Research Sites
127 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.
CONDITIONS
Official Title
Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension
- Hypertension defined as systolic blood pressure 6140 mmHg or diastolic blood pressure 690 mmHg on two occasions at least 4 hours apart
- Hypertension diagnosed according to ACOG definition for pregnancy-related hypertension
- Treatment escalation after enrollment to achieve normal blood pressure
You will not qualify if you...
- History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, or pulmonary edema
- Contraindication to either Nifedipine or Labetalol
- Heart rate less than 60 or greater than 110 beats per minute
- Native language other than English or Spanish
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nebraska Methodist Women's Hospital
Omaha, Nebraska, United States, 68022
Actively Recruiting
Research Team
T
Todd Lovgren, MD
CONTACT
J
Joshua Dahlke, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here